Last updated on December 2019

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma


Brief description of study

The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Clinical Study Identifier: NCT04039607

Find a site near you

Start Over

Local Institution

Wiener Neustadt, Austria
0.68miles
  Connect »